Intervention

Ziprasidone

ClinicalTrials.gov intervention label

How to interpret these research links

Connected source records

This is the original ClinicalTrials.gov intervention label, found in 46 distinct published trials. Registry interventions may represent drugs, devices, procedures or other study activities. A matched term or study association does not establish product equivalence, efficacy or regulatory approval.

Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.

Clinical trials46
Recruiting0
Common conditions25
Lead sponsors shown15
Advertisement

Clinical trials

46 shown
Atypical Antipsychotics Influence on the Safety of the Heart and Monitoring Indicators Model BuildingNCT04446234 · 2021-05-01
UNKNOWN
Proposal To Develop A Rapid And Cost-Effective Diagnostic Test For SchizophreniaNCT03781115 · 2017-11-20
ACTIVE_NOT_RECRUITING
The Efficacy And Safety Of Intramuscular Ziprasidone For Three Days In Patients With Psychotic AgitationNCT02935998 · 2016-10-01
UNKNOWN
Family Intervention in Recent Onset Schizophrenia Treatment (FIRST)NCT02600741 · 2015-07-24
COMPLETED
Evaluation of the Necessity of Long-term Pharmacological Treatment With Antipsychotics in Schizophrenic PatientsNCT02307396 · 2015-02-01
COMPLETED
Pharmacovigilance in Gerontopsychiatric PatientsNCT02374567 · 2015-01-01
TERMINATED
The Role of miR-30 Family Dysregulation in Response to Antipsychotic TreatmentNCT02650102 · 2013-01-01
UNKNOWN
A Randomized Double-blind Trial With 6 Antipsychotic Drugs for SchizophreniaNCT02192723 · 2012-06-01
COMPLETED
Effectiveness of Ziprasidone for Patients With SchizophreniaNCT01198353 · 2010-09-01
COMPLETED
Safety and Efficacy of Aripiprazole and Ziprasidone Among Schizophrenic Patients With Metabolic SyndromeNCT01714011 · 2009-05-01
COMPLETED
Comparative Study of Aripiprazole, Quetiapine and Ziprasidone in Treatment of First Episode Psychosis: 3-year Follow-upNCT02526030 · 2008-10-01
COMPLETED
Ziprasidone Augmentation of SSRIs for Patients With Major Depressive Disorder (MDD) That do Not Sufficiently Respond to Treatment With SSRIsNCT00633399 · 2008-07-01
COMPLETED
A 12-Week, Placebo Controlled Trial of Ziprasidone as Monotherapy for Major Depressive DisorderNCT00555997 · 2008-03-01
COMPLETED
Treatment of Schizophrenic Patients With ZiprasidoneNCT00579670 · 2007-10-01
COMPLETED
Switch Study of Existing Atypical Antipsychotics to BifeprunoxNCT00347425 · 2006-12-01
COMPLETED
Open-label Ziprasidone Study for Psychosis Treatment in AdolescentsNCT00421954 · 2006-05-01
COMPLETED
Preventing Relapse in Schizophrenia: Oral Antipsychotics Compared To Injectables: Evaluating EfficacyNCT00330863 · 2006-05-01
COMPLETED
Treatment With Ziprasidone for Schizophrenia Patients With Obsessive Compulsive Disorder (OCD)NCT00229385 · 2006-01-01
COMPLETED
Efficacy and Safety of Iloperidone Compared With Placebo and Active Control in Subjects With Acute SchizophreniaNCT00254202 · 2005-11-18
COMPLETED
Neurocognitive Effectiveness in Treatment of First-episode Non-affective Psychosis: 1-year Follow-upNCT02534363 · 2005-10-01
COMPLETED
Comparative Study of Aripiprazole, Quetiapine and Ziprasidone in the Treatment of First Episode Nonaffective PsychosisNCT02305823 · 2005-10-01
COMPLETED
Open-Label Study of Geodon in Non-Rapid Cycling Bipolar II Patients With Major DepressionNCT00237666 · 2005-02-01
COMPLETED
Ziprasidone for Clozapine- or Olanzapine-Associated Diabetes MellitusNCT00351000 · 2005-01-01
COMPLETED
A Study of the Efficacy and Safety of Ziprasidone in Patients With Acute Exacerbation of Schizophrenia or Schizoaffective DisorderNCT00645229 · 2004-09-01
TERMINATED
A Study to Compare the Efficacy and Safety of Ziprasidone and Risperidone for the Treatment of Schizophrenia in Chinese PatientsNCT00645372 · 2004-07-01
COMPLETED
A Study Comparing the Efficacy and Safety of Ziprasidone and Aripiprazole for the Treatment fo Schizophrenia or Schizoaffective Disorder in Hospitalized PatientsNCT00634348 · 2004-04-01
COMPLETED
Energy Homeostasis Under Treatment With Atypical AntipsychoticsNCT00148564 · 2004-03-01
COMPLETED
A Study of the Safety and Tolerability of Oral Ziprasidone in Children and Teens With Psychotic DisordersNCT00650611 · 2003-12-01
COMPLETED
Safety And Efficacy Study Of Ziprasidone In Pediatric Psychotic IllnessNCT00199940 · 2003-12-01
COMPLETED
A Study of the Effects of Ziprasidone for the Treatment of Schizophrenia or Schizoaffective Disorder in Patients Who Were Switched From Other Antipsychotic DrugsNCT00649064 · 2003-12-01
COMPLETED
A Study of the Efficacy and Safety of Ziprasidone for the Treatment of Acute Exacerbation of Schizophrenia or Schizoaffective DisorderNCT00650429 · 2003-10-01
COMPLETED
Effect of Ziprasidone on Glucose & Plasma Lipids in Diabetes (II) and Schizophrenia or Schizoaffective DisorderNCT00395031 · 2003-09-01
COMPLETED
A Study of the Efficacy and Safety of Intramuscular Ziprasidone Followed by Oral Ziprasidone for the Treatment of PsychosisNCT00644800 · 2003-07-01
COMPLETED
Mozart Relapse StudyNCT00143351 · 2003-06-01
COMPLETED
A Study Comparing the Safety and Efficacy of Ziprasidone and Risperidone for the Treatment of Chronic SchizophreniaNCT00645515 · 2003-06-01
TERMINATED
Ziprasidone Versus Olanzapine In The Treatment Of Schizophrenia.NCT00239109 · 2003-04-01
COMPLETED
Ziprasidone vs. Sertraline/Haloperidol in Psychotic DepressionNCT00340379 · 2003-04-01
COMPLETED
IM and Oral in Acute Exacerbation of Schizophrenia (BIZET Study)NCT00136994 · 2003-03-01
COMPLETED
Use, Effects and Side-effects of Second-generation Antipsychotics in a Naturalistic SettingNCT00932529 · 2003-02-01
COMPLETED
A Study Comparing the Efficacy and Tolerability of Ziprasidone vs. Clozapine for the Treatment of Schizophrenia in Patients Who Continue to Have Symptoms on or Cannot Tolerate Other Antipsychotic DrugsNCT00649844 · 2003-01-01
COMPLETED
Ziprasidone in Early Onset Schizophrenia Spectrum DisordersNCT01006551 · 2002-12-01
COMPLETED
Extension Study: Evaluating the Safety of Oral Ziprasidone in the Treatment of Subjects With SchizophreniaNCT00139737 · 2002-03-01
COMPLETED
Large Simple Trial (LST) Of Cardiovascular Safety Of Ziprasidone And Olanzapine- (Zodiac)NCT00418171 · 2002-02-01
COMPLETED
Extension Study of Patients Successfully Treated by Ziprasidone in Study A1281031NCT00174447 · 2001-10-01
COMPLETED
Switching Medication to Treat SchizophreniaNCT00044655 · 2001-07-01
COMPLETED
Efficacy and Safety With Ziprasidone in First-episode PsychosisNCT01157559
COMPLETED

Common conditions

Schizophrenia38Schizoaffective Disorder8Psychotic Disorders4Affective Disorders2Bipolar Disorder2Major Depressive Disorder2Acute Exacerbation of Psychosis1Anxiety Disorders1Bipolar II Disorder1Delusional Disorder1Dementia1Depression1Depressive Disorder, Major1First Episode Psychosis1Major Depressive Episode1Mania1Obsessive Compulsive Disorder1Psychosis1Psychosomatic Disorders1Psychotic Disorder1Psychotic Mood Disorder1Schizoaffective Disorders1Schizophrenia and Disorders With Psychotic Features1Schizophrenia and Schizoaffective Disorder1Schizophreniform Disorder1

Leading sponsors

Pfizer's Upjohn has merged with Mylan to form Viatris Inc. 15 Fundación Marques de Valdecilla 3 Massachusetts General Hospital 2 Beijing HuiLongGuan Hospital 1 Charite University, Berlin, Germany 1 Chonbuk National University Hospital 1 Duke University 1 Hannover Medical School 1 Icahn School of Medicine at Mount Sinai 1 Janssen Scientific Affairs, LLC 1 Manhattan Psychiatric Center 1 Medical College of Wisconsin 1 New York State Psychiatric Institute 1 North Suffolk Mental Health Association 1 Northwell Health 1

Trial status mix

COMPLETED39
TERMINATED3
UNKNOWN3
ACTIVE_NOT_RECRUITING1

Phase mix

PHASE422
PHASE314
PHASE27
NA2
PHASE12
Advertisement

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.